Search results for "Cobimetinib"

showing 4 items of 4 documents

Systematic review of BRAF/MEK inhibitors‐induced Severe Cutaneous Adverse Reactions (SCARs)

2020

Severe cutaneous adverse reactions (SCARs) [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic syndrome (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed eruption (GBFE)] are severe drug reactions that often require hospitalization and could be fatal. BRAF and MEK inhibitors (BRAF/MEKi) are a standard of care in patients with BRAF-mutated metastatic melanomas. These agents are administered until disease progression or unacceptable toxicity occurs. This review has focus on BRAF/MEKi-induced SCARs. A systematic search of the following terms: 'vemurafenib', 'cobimetinib', 'dabrafenib', 'trametinib',…

Proto-Oncogene Proteins B-rafmedicine.medical_specialtyDermatologyCicatrix030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansVemurafenibRetrospective StudiesMitogen-Activated Protein Kinase KinasesTrametinibCobimetinibbusiness.industryBinimetinibDabrafenibAcute generalized exanthematous pustulosismedicine.diseaseDermatologyToxic epidermal necrolysisInfectious DiseasesAcute Generalized Exanthematous PustulosischemistryDrug Hypersensitivity SyndromeStevens-Johnson Syndrome030220 oncology & carcinogenesisbusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

2020

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular pre…

0301 basic medicineOncologyProto-Oncogene Proteins B-rafmedicine.medical_specialtyPredictive molecular pathologyLung NeoplasmsGene mutationBRAF03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansNon-Small-Cell LungVemurafenibLung cancerneoplasmsMelanomaTrametinibCobimetinibbusiness.industryBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology; Biomarkers; Humans; Mutation; Proto-Oncogene Proteins B-raf; Carcinoma Non-Small-Cell Lung; Lung Neoplasms; MelanomaCarcinomaPrecision medicineDabrafenibHematologyBiomarkerPrecision medicinemedicine.diseaseBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathologyLung Neoplasm030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMutationPersonalized medicineLung cancerbusinessBiomarkersmedicine.drugHuman
researchProduct

Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome

2019

OncologyCobimetinibmedicine.medical_specialtyCombination therapybusiness.industryMelanomaPosterior reversible encephalopathy syndromeHematologymedicine.diseasechemistry.chemical_compoundText miningOncologychemistryInternal medicinemedicineVemurafenibbusinessmedicine.drugAnnals of Oncology
researchProduct

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treat…

2017

Abstract Lessons Learned Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents. The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested. Background KRAS-mutant tumors possess abnormal mitogen-activated protein kinases (MAPK) pathway signaling, leading to dysregulated cell proliferation. Cobimetinib blocks MAPK signaling. The dual-action antibody duligotuzumab (MEHD7945A) inhibits ligand binding to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). Blockade of EGFR/HER3 and inhibitio…

Male0301 basic medicineOncologyMAPK/ERK pathwayCancer ResearchReceptor ErbB-3MAP Kinase Kinase 1Administration Oralmedicine.disease_causechemistry.chemical_compound0302 clinical medicinePiperidinesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesEpidermal growth factor receptor31biologyMiddle AgedErbB ReceptorsTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisFemaleDrug EruptionsKRASmedicine.symptomColorectal NeoplasmsSignal TransductionAdultmedicine.medical_specialty4HypokalemiaAcneiform eruptionProto-Oncogene Proteins p21(ras)03 medical and health sciencesAcneiform EruptionsInternal medicineHumansAdverse effectAgedNeoplasm StagingCobimetinibDose-Response Relationship Drugbusiness.industryClinical Trial Resultsmedicine.disease030104 developmental biologychemistryAstheniaImmunoglobulin Gbiology.proteinAzetidinesbusinessProgressive diseaseThe Oncologist
researchProduct